PrecisionLife and PharmEnable have announced a new drug discovery partnership, collaborating to develop novel treatments for Amyotrophic Lateral Sclerosis (ALS).
We are joined by academic partners Professor Ammar Al-Chalabi from King’s College London, and Dr Laura Ferraiuolo at the Sheffield Institute for Translational Neuroscience (SITraN), world leading experts in the neurobiology of ALS.
ALS is a devastating condition that causes the progressive degeneration of nerve cells that control muscle movements. Currently available treatments can help slow down disease progression and control symptoms, but there is no known cure.
Dr Steve Gardner, CEO of PrecisionLife, said: “Our partnership with PharmEnable brings together evidence-led innovation in targets and small molecule leads for complex diseases. We believe that through this partnership, we will be able to develop a number of effective new medicines, and we aim to create new options for patients with ALS.”
With this partnership, PrecisionLife and PharmEnable bring an innovative data-driven approach to drug discovery, aiming to discover a novel treatment for ALS. The partnership will expand to cover other disease areas in the future.